WEBULL

How Investors Are Reacting To DENTSPLY SIRONA (XRAY) Appointing an Interim CFO With Turnaround Expertise

Simply Wall St · 2d ago
  • On November 25, 2025, DENTSPLY SIRONA Inc. announced that veteran finance executive Michael Pomeroy had been appointed interim Chief Financial Officer, while President and CEO Daniel T. Scavilla continues as the company’s principal financial officer until a permanent CFO is named.
  • Pomeroy’s track record guiding complex industrial, healthcare, retail, and medical device businesses through growth, turnarounds, and M&A adds experienced financial oversight at a time when DENTSPLY SIRONA is pursuing operational improvement and portfolio refinement.
  • We’ll now explore how bringing in an interim CFO with turnaround and M&A experience could influence DENTSPLY SIRONA’s long-term recovery narrative.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

DENTSPLY SIRONA Investment Narrative Recap

To own DENTSPLY SIRONA, you need to believe its mix of digital dentistry, implants, and global distribution can return to sustainable growth despite recent revenue pressure and impairments. The interim CFO appointment looks more like a stabilizing move than a change to the near term catalysts, which still hinge on execution of cost reduction programs, tariff mitigation, and reigniting demand in high margin elective categories. The biggest risk remains that weak top line trends and tariff headwinds persist.

The recent Q3 2025 results and updated 2025 guidance, which point to net sales of US$3.6 billion to US$3.7 billion and continued year over year declines, frame the context for this finance leadership change. With fresh impairment charges linked to tariffs and softer volumes in equipment, implants, and prosthetics, an interim CFO with turnaround and M&A experience could be important in preserving balance sheet flexibility while management pushes operational streamlining and digital dentistry initiatives like DS Core.

Yet investors should also weigh how prolonged tariff related cost pressure could affect margins and capital allocation over the next few years...

Read the full narrative on DENTSPLY SIRONA (it's free!)

DENTSPLY SIRONA's narrative projects $3.9 billion revenue and $502.2 million earnings by 2028.

Uncover how DENTSPLY SIRONA's forecasts yield a $12.96 fair value, a 15% upside to its current price.

Exploring Other Perspectives

XRAY Community Fair Values as at Dec 2025
XRAY Community Fair Values as at Dec 2025

Three members of the Simply Wall St Community currently see fair value for DENTSPLY SIRONA between US$12.96 and US$34.81, reflecting very different outlooks on recovery. Before leaning on any one view, it is worth considering that ongoing sales weakness and repeated impairments have already challenged expectations for a smooth turnaround, which can influence how confidently the company can invest in growth and margin improvement.

Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth just $12.96!

Build Your Own DENTSPLY SIRONA Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.